Insulin-like growth factor binding protein-2, 28 kDa an 24 kDa insulin-like growth factor binding protein levels are decreased in fluid of dominant follicles, obtained from normal and polycystic ovaries by Schuller, A.G.P. (Alwin) et al.
Regulatory Peptides, 48 (1993) 157-163 
© 1993 Elsevier Science Publishers B.V. All rights reserved 0167-0115/93/$06.00 
157 
REGPEP 01566 
Insulin-like growth factor binding protein-2, 28 kDa and 24 kDa 
insulin-like growth factor binding protein levels are decreased in fluid 
of dominant follicles, obtained from normal and polycystic ovaries 
A.G.P. Schuller a, D.J. Lindenbergh-Kortleve a, T.D. Pache b, E.C. Zwarthoff c, B.C.J.M. Fauser b
and S.L.S. Drop a 
a Department of Pediatrics, Subdivision of Pediatric Endocrinology, b Department of Obstetrics and Gynecology, Section of Reproductive 
Endocrinology and Fertility, and c Department of Pathology, Erasmus University, Dijkzigt University Hospital, Sophia Children's Hospital, 
Rotterdam (The Netherlands) 
(Received 21 April 1993; accepted 25 May 1993) 
Key words: Insulin-like growth factor binding protein; Insulin-like growth factor; Ovary; Follicle; Human 
Summary 
In order to investigate potential changes in insulin-like growth factor binding proteins (IGFBPs) during 
human follicle maturation, we examined the IGFBP profiles in follicular fluid from follicles in different stages 
of maturation. Samples were obtained from ovaries of women with regular menstrual cycles and of subjects 
with cycle abnormalities and polycystic ovaries (diagnosed as polycystic ovary syndrome (PCOS)) and ana- 
lyzed by Western ligand blotting. IGFBPs of 43 kDa, 37 kDa, 31 kDa, a doublet around 28 kDa and a minor 
band of 24 kDa were detected in follicle fluid of normal non-dominant (size < 10 mm) and atretic 
(androstenedione/estradiol rat  > 4) follicles of both regularly menstruating women and PCOS patients. The 
43 and 37 kDa IGFBPs could be identified as IGFBP-3 and the 31 kDa IGFBP as IGFBP-2, whereas the 
28 kDa IGFBP could not be identified as IGFBP-1, all by immunoblotting techniques. A dramatic decrease 
in IGFBP-2, the 28 kDa and 24 kDa IGFBPs was observed in follicular fluid of dominant follicles (size > 10 
mm) of both regular menstruating individuals and one PCOS patient as compared with follicular fluid of normal 
non-dominant or atretic follicles. These observations indicate that the PCOS follicle may not be different from 
normal with respect to IGFBP profiles. Furthermore, these results uggest that at least one of these IGFBPs 
might be involved in human folliculogenesis. 
Correspondence to." A.G.P. Schuller, Laboratory for Molecular Endocrinology, Erasmus University Rotterdam, Room 1022, P.O. Box 1738, 
3000 DR Rotterdam, The Netherlands. 
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Introduction 
The insulin-like growth factors (IGFs) are low mo- 
lecular weight peptides with both metabolic and mi- 
togenic properties believed to play a role in ovarian 
function [1,2]. In the human preovulatory granulosa 
cell, expression of IGF-II mRNA but not IGF-I 
mRNA has been detected [ 3 ]. Human granulosa cells 
contain transcripts for both the type I and type II 
IGF receptor [4] and contain the type I IGF recep- 
tor on their surface [5]. In human granulosa cells, 
isolated from polycystic ovaries, IGF-I synergizes 
with follicle-stimulating hormone (FSH) and human 
chorionic gonadotropin (hCG) in increasing 17/~- 
estradiol (E2) production, suggesting a role for IGF-I 
in enhancing onadotropin action in human follicu- 
logenesis [6]. 
In serum and extracellular fluids, the IGFs are 
present bound to high affinity binding proteins (IG- 
FBPs). These IGFBPs comprise a family of six 
structurally related proteins [7], which modulate IGF 
action [8]. In human follicular fluid several of these 
IGFBPs have been found and one such species, 
IGFBP-1, was localized in luteinized granulosa cells 
[9]. Human granulosa cells express mRNA for 
IGFBP-1 [10]. In addition, IGFBP-1 was reported 
to inhibit IGF induced proliferation of human granu- 
losa cells, suggesting that IGFBP-1 is one of the 
endogenous factors regulating rowth and differen- 
tiation of human granulosa cells [ 11]. IGFBP-2, -4 
and -5 mRNA expression was found mainly in 
granulosa of atretic follicles and IGFBP-4 and -5 
gene expression was located primarily in theca and 
stromal cells. Gene expression of IGFBP-3 was de- 
tected in theca of all stages tested and was selectively 
expressed in granulosa cells of dominant follicles 
[ 12]. IGFBP-3 has been shown to inhibit IGF-I and 
FSH induced estrogen production by cultured human 
granulosa cells [ 13], suggesting that this binding pro- 
tein may modify FSH actions. 
Since there is mounting evidence that the IGF 
system, complete with ligands, IGF-receptors and 
IGFBPs, is present in the human ovary, we decided 
to investigate potential changes in IGFBPs during 
follicle maturation. Therefore, we examined the 
IGFBP profiles in fluid from follicles in different 
stages of maturation obtained from ovaries of women 
with regular menstrual cycles and of PCOS patients 
presenting with cycle abnormalities. 
Materials and Methods 
Follicular fluid samples 
16 women volunteered toparticipate in this study, 
which was approved by the local Ethics Review 
Committee. Their mean age was 33 years (range 27- 
44) and they all were regularly menstruating with a 
mean cycle length of 28 + 2 days (mean + S.D.). Fol- 
licular fluid samples were collected through puncture 
of individual follicles as described previously [ 14]. In 
addition, follicle fluid was obtained from five infertile 
PCOS women. Four patients presented with amen- 
orrhea and one with severe oligomenorrhea (cycle 
length 72-84 days). All five fullfilled our criteria for 
transvaginal sonographic diagnosis of polycystic 
ovaries; (1) ovarian volume above 8.0 ml, (2) > 11 
follicles between 2 and 10 mm in size in each ovary, 
and (3) increased ovarian stroma echogenecity [15]. 
The mean age of these patients was 28 years, two 
women were obese (BMI > 25 kg/m 2) and hirsute, 
one woman was hirsute only. Serum hormone con- 
centrations were 10.6 (range 7.9 to 12.1) IU/1 for 
luteinizing hormone (LH), and 6.9 (range 3.9 to 8.3) 
IU/1 for follicle stimulating hormone (FSH) esti- 
mated by immunoradiometric assays. Radioimmu- 
noassay serum determinations for serum testoster- 
one were 2.9 (range 1.6 to 7.2) nmol/1. All FF samples 
were divided into three groups (depending on their 
androstenedione/estradiol (AD/E2) ratio as de- 
scribed by McNatty et al. [16]) and pooled per in- 
dividual. Group A (normal non-dominant follicles): 
AD/E 2 ratio <4 and a diameter < 10 ram, group B 
(atretic follicles): AD/E 2 ratio >4 and group D 
(dominant follicles): AD/E 2 ratio <4 and a size > 10 
mm. 
Western ligand blotting 
Western ligand blots were prepared essentially as 
described by Hossenlopp et al. [17]. FF samples (3 
/~1) were applied to a 9~o sodium dodecylsulfate 
(SDS)-polyacrylamide g l, run under non-reducing 
conditions, and the separated proteins were trans- 
ferred onto nitrocellulose filters by electroblotting. 
The filters were washed with 3~o NP-40 in 100 mM 
Tris-HC1, pH 7.5/0.9~o NaC1 (TBS), 3~o BSA in 
TBS, and then incubated with 500,000 cpm 
[125I]IGF-II (kindly provided by Dr. S. van Buul- 
Offers, Wilhelmina Childrens Hospital, Utrecht The 
Netherlands) for 14 h at 4°C. Subsequently, filters 
were washed and exposed to Kodak X-Omat AR 
film with intensifying screen at -70°C. for up to 14 
days. 
Immunoblotting 
After autoradiography, filters were immunostained 
using either a monoclonal ntibody against IGFBP-1 
[ 18], a polyclonal antibody against IGFBP-2 (kindly 
provided by Dr. J. Schwander, Kantonspital Basel, 
Switzerland) or a polyclonal antibody against IG- 
FBP-3 (kindly provided by Dr. R. Rosenfeld, Stan- 
ford University Stanford, USA) using standard pro- 
cedures. Briefly, filters were incubated with 3 ~o B SA 
in TBS followed by incubation with an IGFBP spe- 
cific antibody. Filters were washed in 0.1 ~o NP-40 
in TBS and incubated with an alkaline-phosphatase 
coupled second antibody. Finally, filters were washed 
and stained with 4-nitro blue tetrazolium chloride 
and 5-bromo-4-chloro-3-indolylphosphate (Bo - 
hringer, Mannheim). 
Quantification of IGFBP levels was performed by 
densitometric s anning of autoradiograms u ing an 
image analyzer (IBAS 2000 Zeiss Kontron, 
Oberkochen, Germany) and the Kontron IBAS1 
version 4.4 software program supplied. Mean inten- 
sities were calculated from measurements of autora- 
diograms of at least four samples and statistical con- 
fidence of differences calculated using Student's 
t-test. 
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Results 
Follicle fluid (FF) samples obtained from individu- 
als with regular cycles were subjected to SDS-PAGE 
and Western ligand blotting using iodinated IGF-II. 
As shown in Fig. 1, two major bands of 43 and 37 
kDa, corresponding to the glycosylated forms of 
IGFBP-3, were detected. In addition a band of 31 
kDa, a doublet around 28 kDa and a minor band of 
approx. 24 kDa (corresponding to the molecular 
mass of IGFBP-2, IGFBP-1 and IGFBP-4, respec- 
tively) were seen (Fig. 1). Using a polyclonal anti- 
body specific for IGFBP-3, we were able to show 
that the 43 and 37 kDa bands were indeed isoforms 
of IGFBP-3 (Fig. 2a). The 31 kDa band was iden- 
tified as IGFBP-2 by immunoblotting (Fig. 2b). 
However, the 28 kDa IGFBP doublet did not react 
with a specific antibody against IGFBP-1, whereas 
the antibody clearly detected the positive control 
(IGFBP-1 in amniotic fluid), indicating that this 28 
kDa IGFBP was not IGFBP-1 (Fig. 2c). 
Comparison of the Western ligand blot profile of 
the IGFBPs in FF of follicles in different stages of 
development, revealed that in all dominant follicles, 
IGFBP-2, the 28 kDa and the 24 kDa IGFBP were 
strongly decreased, as compared to normal follicles 
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Fig. 1. Autoradiograph of a representative Western ligand blot of 
equal volumes (3/~1) of follicular fluid from normal non-dominant 
follicles (left lane) and atretic follicles (right lane) obtained from 
one individual. Molecular mass markers (in kDa) are indicated by 
a/TOWS. 
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Fig. 2. Immunostaining of a representative Western blot of equal 
volumes (3 #1) of follicular fluid from normal non-dominant (lanes 
1), atretic (lanes 2) and dominant (lanes 3) follicles obtained from 
one regularly menstruating individual. Filters are stained using a 
polyclonal antibody against IGFBP-3 (A), IGFBP-2 (B) and a 
monoclonal antibody against IGFBP-1 (C). Amniotic fluid (lane 
AF) was used as a positive control to detect IGFBP-1. 
(Fig. 3). Most atretic follicles, diagnosed based on 
Ad/E 2 ratio >4, showed no difference in IGFBP 
profiles as compared to normal follicles (Fig. 3). Only 
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Fig. 3. Autoradiograph of a representative Western ligand blot of 
equal volumes (3/tl) of follicular fluid from normal non-dominant 
(left lane), atretic (middle lane) and dominant (right lane) follicles 
obtained from a single regularly menstruating individual. Molecu- 
lar mass markers (in kDa) are indicated by arrows. 
in two samples classified as FF of atretic follicles, a 
decrease in IGFBP-2 and the 28 kDa and 24 kDa 
IGFBPs was observed (results not shown). 
In FF samples obtained from five PCOS patients 
IGFBP profiles were also determined. When com- 
pared to FF of normal and atretic follicles of regu- 
lar cycling women, no dramatic difference in IGFBP 
profiles could be observed (Fig. 4). One of the PCOS 
patients developed a dominant follicle. In FF of this 
follicle the same decrease in IGFBP-2, 28 kDa 
IGFBP and 24 kDa IGFBP was observed as seen 
in the dominant follicles of regular cycling individu- 
als (Fig. 4), showing no difference in IGFBP profile 
between FF of follicles obtained from PCOS patients 
or regularly menstruating women. 
In order to quantify differences in IGFBP levels, 
autoradiograms were analyzed by densitometric 
scanning. The mean relative IGFBP-2 levels in fluid 
of normal non-dominant (100 + 52 %) and atretic fol- 
licles (50 + 23 %, n = 6) was not significantly different 
(P> 0.05). Also no significant difference between the 
relative 24 kDa IGFBP levels could be observed 
(100+ 39%, n=6 for normal non-dominant and 
69 + 21%, n = 6 for atretic follicles). Valid quantifi- 
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Fig. 4. Autoradiograph ofa representative Western ligand blot of 
equal volumes (3/~1) of follicular fluid from normal non-dominant 
(left lane), atretic (middle lane) and dominant (right lane) follicles 
obtained from a single PCOS patient. Molecular mass markers (in 
kDa) are indicated by arrows. 
cation of the differences in IGFBP-2, the 28 kDa 
IGFBP and the 24 kDa IGFBP levels between fol- 
licle fluid of normal non-dominant and dominant 
follicles could not be made due to the dramatic de- 
crease in the intensities of these IGFBPs in fluid of 
the dominant follicles. 
Discussion 
Results presented show that follicle fluid of healthy 
follicles obtained from regularly menstruating women 
contain IGFBPs with a molecular mass of 43, 37, 31, 
28 and 24 kDa. Using standard immunoblotting 
techniques, we were able to identify the 43 and 37 
kDa bands as IGFBP-3 and the 31 kDa protein as 
IGFBP-2. The 28 kDa doublet, however, could not 
be identified as IGFBP-1. Recently, Cataldo and 
Giudice also reported the presence of a 28 and 24 
kDa band in follicular fluid. The 28 kDa IGFBP was 
shown to be glycosylated, and upon deglycosylation 
this protein most likely comigrated with 24 kDa 
IGFBP, because no additional band was found. 
Since indeed a glycosylated variant of IGFBP-4 was 
reported [19,20], the authors suggested that the 28 
kDa and 24 kDa IGFBPs found in follicular fluid 
were the glycosylated and non-glycosylated forms of 
IGFBP-4 [21]. Alternatively, the 28 kDa glycosy- 
lated IGFBP could be IGFBP-6. This IGFBP has 
been shown to contain a potential Asn-linked glyco- 
sylation site, but is up to now only detected in por- 
cine follicular fluid [22]. Furthermore, no IGFBP-6 
mRNA expression could be observed in any cell type 
of the human ovary [12]. Finally, since the 28 kDa 
IGFBP is a doublet, the possibility exists that this 
doublet represents both IGFBP-4 and IGFBP-6. 
Comparison of the IGFBP profiles in follicular 
fluid samples of follicles in different stages of devel- 
opment revealed that their was no dramatic hange 
in IGFBPs in follicular fluid of normal healthy non- 
dominant follicles as compared to atretic follicles. 
Only in two out of 12 pools of atretic follicles a de- 
crease in IGFBP-2, the 28 kDa and 24 kDa IGFBP 
(presumably IGFBP-4), was observed. Furthermore, 
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no differences in IGFBP profiles were observed be- 
tween follicular fluid samples obtained from PCOS 
patients and regularly menstruating women. From 
one PCOS patient follicular fluid was obtained from 
a dominant follicle, showing the same decrease in 
IGFBP-2, the 28 kDa and 24 kDa IGFBPs as seen 
in regularly menstruating women, indicating that with 
respect o the IGFBPs, follicular fluid of PCOS pa- 
tients is not different from normal. These observa- 
tions are in contrast with previous findings. Cataldo 
and Giudice described 3-, 6- and 19-fold higher 
amounts of IGFBP-2, 28 kDa and 24 kDa IGFBPs, 
respectively, in follicular fluid of atretic ompared to 
healthy follicles and these changes in IGFBP levels 
were also observed in follicular fluid obtained from 
three PCOS patients [21,23]. Some of this disagree- 
ment might be explained by the way atretic and 
healthy follicles are defined. We have classified the 
follicles according to AD/E2 ratios as validated pre- 
viously [ 16], whereas E2/T was used by Cataldo and 
Giudice. Secondly, our group of PCOS patients is 
defined according to rigid clinical (obesity, hirsut- 
ism), endocrine (hyperandrogenemia) and sono- 
graphic (polycystic ovaries) criteria, as described 
previously [ 15]. Finally, the most striking differences 
between atretic and healthy non-dominant follicles 
noted [21] might be found only in a subgroup of 
these follicles (namely those with a E2/T ratio of 
136-500). 
A dramatic decrease in IGFBP-2, the 28 kDa and 
24 kDa IGFBPs was observed in all samples of 
dominant follicles tested as compared to healthy de- 
veloping non-dominant follicles. This finding seems 
of special interest since several studies indicate that 
the IGFBPs may play a role in regulating the poten- 
tial of IGF to enhance gonadotropin action and sub- 
sequent follicle development [24-26]. Both IG- 
FBP-1 and IGFBP-3 have been shown to inhibit 
IGF-I and FSH induced estrogen production by cul- 
tured human granulosa cells. These IGFBPs were 
also capable of inhibiting the IGF-I, but not FSH 
induced progesterone r sponse [13], demonstrating 
the inhibitory effect of these IGFBPs on the IGF-I- 
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stimulated granulosa cell steroidogenesis. Further- 
more, IGFBP-1  has been shown to inhibit the DNA 
amplification induced by IGFs  in human granulosa- 
luteal cells [11]. Also, a role for the IGFBPs  not 
directly related to their IGF  binding capacity has 
been proposed. Bicsak et al. showed that, like an 
IGF- I  antiserum, IGFBP-2  and -3 were capable of 
inhibiting steroid production by granulosa cells, but 
that IGFBP-3  was 2-3-fold more potent then 
IGFBP-2.  Furthermore, the IGFBPs  had no effect 
on the IGF- I  stimulated cAMP production induced 
by FSH,  suggesting that IGFBPs  may have alterna- 
tive ways of action, other than IGF  sequestration 
[271. 
In summary, it may be concluded from this study 
that IGFBP-2,  the 28 kDa and 24 kDa IGFBPs  are 
decreased in the dominant follicles as compared to 
normal healthy non-dominant and atretic follicles. A 
decrease of the inhibitory IGFBPs  may result in an 
increase in free IGFs  resulting in a stimulation of the 
mitogenic response of granulosa cells and an ampli- 
fied steroidogenic response to FSH stimulation. This 
in turn facilitates the follicle to gain dominance. Fur- 
thermore, no differences in the IGFBP follicle fluid 
profile between PCOS and regularly menstruating 
women could be observed, which may suggest hat 
with respect to intra-ovarian IGFBPs ,  PCOS pa- 
tients are not different from normal. 
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